Prevalence and significance of acanthosis nigricans in children and adolescents

Annals of Saudi Medicine

Volumn 16, Issue 4, 1996, Pages 424-428

  Soliman, Ashraf T ^a   Al Suwaid, Abdul Raouf ^b   Gamil, Hani ^b   Asfour, Maurice ^c  

^a ROYAL HOSPITAL   (Oman)

^b Al Nahda Hospital   (Oman)

^c Deptartment of Endocrinology   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FOLLITROPIN; GLUCAGON; HYDROCORTISONE; LUTEINIZING HORMONE; PROLACTIN; TESTOSTERONE; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL;

ACANTHOSIS NIGRICANS; ADOLESCENT; ARTICLE; BLOOD LEVEL; BODY MASS; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERINSULINEMIA; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OMAN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029788642     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.1996.424     Document Type: Article

References (32)

1. Flier JS. Metabolic importance of acanthosis nigricans. Arch Dermatol 1985;121:193-4.
2. Flier JS, Eastman RC, Minaker KL, Matteson D, Rowe JR. Acanthosis nigricans in obese women with hyperandrogenism. Diabetes 1985;34:101-7.
3. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65:499-502.
4. Hud AJ, Cohen JB, Wagner JM, Cruz PD. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992;128:941-4.
5. Khan RC, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. N Engl J Med 1976;294:739-45.
6. Rendon M, Cruz PD, Sontheimer RD, Bergstresser PR. Acanthosis nigricans: a cutaneous marker for tissue resistance to insulin. Am Acad Dermatol 1989;21:461-9.
7. Griffiths WAD, Leigh IM, Marks R. Disorders of keratinization. In: Champion RH, Burton JL, Ebling FJG, eds. Textbook of Dermatology, 5th ed. London: Blackwell Scientific Publications, 1992:1384-7.
8. Rolland-Cachera MF, Sempe M, Guilloud-Bataille M, et al. Adiposity indices in children. Am J Clin Nutr 1982;36:178-84.
9. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
10. World Health Organization Expert Committee on Diabetes Mellitus. Second report. Technical report series 646. Geneva: WHO 1980.
11. Faber OK. Beta-cell function and diabetic control in insulin-dependent diabetes mellitus. Acta Endocrinol 1985;110(suppl):73-8.
12. Forest MG. Adrenal steroid deficiency states. In: Brook CGD, ed. Clinical Paediatric Endocrinology, 2nd ed. London: Blackwell, 1989:368-406.
13. Curth HO, Hilberg AW, Machacek GF. The site and histology of the cancer associated with acanthosis nigricans. Cancer 1962;15:364-82.
14. Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med 1989;87:269-72.
15. Peters EJ, Stuart GA, Prince MJ. Acanthosis nigricans and obesity: acquired and intrinsic defects in insulin action. Metabolism 1986;35:807-13.
16. Glass AR. Endocrine aspects of obesity. Med Clin N Am 1989;73:139-60.
17. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-9.
18. Kahn CR, Neville DM Jr, Roth J. Insulin receptor interaction in the obese hyperglycemic mouse. A model of insulin resistance. J Biol Chem 1973;248:244-50.
19. Forgue ME, Freychet P. Insulin receptors in the heart muscle. Demonstration of specific binding sites and impairment of insulin binding in plasma membranes of the obese hyperglycemic mouse. Diabetes 1975;24:715-23.
20. Kosmokos FC, Roth J. Insulin-induced loss of the insulin receptor in IM-9 lymphocytes. J Biol Chem 1980;255:9860-9.
21. Lipson KE, Kolhatkar AA, Donner DB. Cell surface proteolysis and down-regulation of the hepatic insulin receptor. J Biol Chem 1988;263:10495-501.
22. Le Marchand Y, Loten EG, Assimacopoulos-Jeannet F, Forgue ME, Freychet P, Jeanrenaud B. Effect of fasting and streptozocin in the obese hyperglycemic (ob/ob) mouse. Apparent lack of relationship between insulin-binding and insulin effects. Diabetes 1977;26:582-90.
23. Kodama H, Fujita M, Yamaguchi I. Development of hyperglycemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db-db) mice. Diabetologia 1994;37:739-44.
24. Olefsky JM. Obesity. In: Wilson JD, Braunwald E, Isselbacker KJ, et al., eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill International Book Co., 1991:413-4.
25. Baxter RC, Brown AS, Turtle JR. Association between serum insulin, serum somatostatin and liver receptors for human growth hormone in streptozotocin diabetes. Horm Metab Res 1980;12:377-81.
26. Holly JMP, Bridlecombe RA, Dunger RB. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin: a new role for insulin? Clin Endocrinol 1988;29:667-75.
27. Orskov H, Wolthers T, Grofte T. Somatostatin-stimulated insulin-like growth factor binding protein-1 release is abolished by hyperinsulinemia. J Clin Endocrinol Metab 1994;78:138-40.
28. Flier JS. Syndromes of insulin resistance. In: Principles and practice of endocrinology and metabolism. Becker KL, Bilezikian JP, Bremmer WJ, et al., eds. Philadelphia: JP Lippincott Co., 1990:1118-27.
29. Ober KP. Acanthosis nigricans and insulin resistance associated with hypothyroidism. Arch Dermatol 1985;121:229-31.
30. Curth OH. Pituitary basophilism in the juvenile type of acanthosis nigricans. J Am Med Assoc 1955;157:266-7.
31. Brown J, Winkelmann RK, Randall RF. Acanthosis nigricans: a study of 90 cases. Medicine 1968;47:33-51.
32. Randle HW, Winkelmann RK. Steroid-induced acanthosis nigricans in dermatomyositis. Arch Dermatol 1979;115:587-8.